ERBB2 and breast carcinoma: In the clinical trial BOLERO-1, adding everolimus to the combination of trastuzumab and paclitaxel provided a seven-month PFS (progression-free survival) benefit in patients with HR-negative, HER2-positive advanced breast cancer (Hurvitz et al., 2015).